Hyungjun Jeon, Ph.D.
Department of Microbiology & Immunology
Albert Einstein College of Medicine
Forchheimer Building, Room 405
Bronx, NY 10461
Dr. Hyungjun Jeon received his PhD in 2006 from Chung-Ang University (Korea). After graduation, he worked in Ewha Woman’s University as a postdoctoral fellow studying atherosclerosis and immunological responses. From 2008 to 2010, he worked at Dong-A pharmaceuticals for developing anti-premature ejaculation medicine and anti-gastritis medicine. In July 2010, Hyungjun started his postdoctoral training with Dr. Xingxing Zang and is currently studying new pathways for T cell costimulation and coinhibition and related diseases.
Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clinical Cancer Research, in press
Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X. Structure and cancer immunotherapy of the B7 family member B7x. Cell Reports, 9:1089-1098, 2014
Scandiuzzi L, Ghosh K, Hofmeyer KA, Abadi YM, Lázár-Molnár E, Lin EY, Liu Q, Jeon H, Almo SC, Chen L, Nathenson SG, Zang X. Tissue-expressed B7-H1 (PD-L1) critically controls intestinal inflammation. Cell Reports, 6:625-632, 2014.
Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD, Zang X. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Proceedings of the National Academy of Sciences USA, 110:9879-9884, 2013.
Jeon H, Ohaegbulam KC, Abadi YM, Zang X. B7x(B7-H4/B7S1) and myeloid derived suppressor cells in the tumor microenvironment: A tale of two cities. OncoImmunology, e24744-1-e24744-3, 2013
Abadi YM*, Jeon H*, Ohaegbulam KC, Scandiuzzi L, Ghosh K, Hofmeyer KA, Lee JS, Ray A, Gravekamp C, Zang X. Host B7x promotes pulmonary metastasis of breast cancer. The Journal of Immunology, 190:3806-3814, 2013.
Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion (Review). Journal of Biomedicine and Biotechnology, 2011:451694, 2011
Jeon HJ, Choi JH, Jung IH, Park JG, Lee MR, Lee MN, Kim B, Yoo JY, Jeong SJ, Kim DY, Park JE, Park HY, Kwack K, Choi BK, Kwon BS, Oh GT. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation, 121:1124-33, 2010
Kim SK, Ahn KH, Ji JE, Choi JM, Jeon HJ, Jung SY, Jung KM, Kim DK. Neutral sphingomyelinase 2 induces dopamine uptake through regulation of intracellular calcium. Cellular Signalling, 22:865-870, 2010
Kim SK, Ahn KH, Jeon HJ, Lee DH, Jung SY, Jung KM, Kim DK. Purification of neutral sphingomyelinase 2 from bovine brain and its calcium-dependent activation. Journal of Neurochemistry, 112:1088-97, 2010
Kang MS, Ahn KH, Kim SK, Jeon HJ, Ji JE, Choi JM, Jung KM, Jung SY, Kim DK. Hypoxia-induced neuronal apoptosis is mediated by de novo synthesis of ceramide through activation of serine palmitoyltransferase. Cellular Signalling, 22:610-8, 2010
Kang MS, Jeong JY, Seo JH, Jeon HJ, Jung KM, Chin MR, Moon CK, Bonventre JV, Jung SY, Kim DK. Methylmercury-induced toxicity is mediated by enhanced intracellular calcium through activation of phosphatidylcholine-specific phospholipase C. Toxicology and Applied Pharmacology, 216:206-15, 2006
Kim SK, Jung SM, Ahn KH, Jeon HJ, Lee DH, Jung KM, Jung SY, Kim DK. Identification of three competitive inhibitors for membrane-associated, Mg2+-dependent and neutral 60 kDa sphingomyelinase activity. Archives of Pharmacal Research, 28:923-9, 2005
Jeon HJ, Lee DH, Kang MS, Lee MO, Jung KM, Jung SY, Kim DK. Dopamine release in PC12 cells is mediated by Ca(2+)-dependent production of ceramide via sphingomyelin pathway. Journal of Neurochemistry, 95:811-20, 2005